# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN-TD
- Date: 1915-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology. **S**

## History of present illness

Mr. London stopped drinking on the morning after his intake visit and took the five-day chlordiazepoxide taper as prescribed, with a daily telephone check from the nurse. The first three days brought sweats, a tremor and poor sleep, at worst a CIWA-Ar of 11 on the second day, with no hallucinations or seizures; by the fifth day the tremor had gone, and he has had no alcohol since. He missed two mornings of writing and has written his thousand words every other day. He has taken losartan 50 mg daily without dizziness and stopped naproxen; acetaminophen eases his knee. His ankles are less swollen. He has seen the clinic's addiction counselor once. The insurance examination report has arrived, confirming a creatinine of 1.7 mg/dL about fourteen months ago. Ultrasound and liver elastography were done this morning. He sees Dr. Mbatha-Rasmussen of nephrology this afternoon. **S**

| Element | Detail |
|---|---|
| Alcohol | None for twelve days; withdrawal completed, peak CIWA-Ar 11 |
| Losartan | 50 mg daily for two weeks; no side effects |
| Potassium and creatinine | 4.9 mmol/L; 2.04 mg/dL (eGFR 42), up 3 percent |
| Earlier creatinine | 1.7 mg/dL about fourteen months ago |
| Ultrasound | Kidneys normal in size, echogenic, no stones or obstruction; fatty liver |
| Elastography | Liver stiffness 7.2 kPa |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired, but sleeping better than last week |
| Cardiovascular | Positive | Ankle swelling less |
| Genitourinary | Negative | No flank pain or blood in the urine |
| Neurological | Negative | Tremor gone; no confusion |
| Psychiatric | Positive | Restless and irritable; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Losartan 50 mg oral tablet once daily **S**
- Thiamine 100 mg oral tablet once daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen **S**
- Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines **S**

## Allergies

- No known allergy **S**

## Objective

BP 146/92 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 83.6 kg; BMI 27.9 kg/m². All vital signs are synthetic.

Potassium: 4.9 mmol/L; Creatinine: 2.04 mg/dL (high); eGFR (CKD-EPI 1910): 42 mL/min/1.73 m² (low); AST: 49 U/L (high); ALT: 36 U/L; GGT: 141 U/L (high). All results are synthetic.

## Change since baseline

- Potassium: 4.6 mmol/L at baseline, 4.9 mmol/L at this visit **S**
- Creatinine: 1.98 mg/dL (high) at baseline, 2.04 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 1910): 43 mL/min/1.73 m² (low) at baseline, 42 mL/min/1.73 m² (low) at this visit **S**
- AST: 68 U/L (high) at baseline, 49 U/L (high) at this visit **S**
- ALT: 41 U/L at baseline, 36 U/L at this visit **S**
- GGT: 186 U/L (high) at baseline, 141 U/L (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 146/92, pulse 84; weight 83.6 kg |
| Cardiovascular | Regular rhythm; no murmur; trace ankle edema |
| Neurological | No tremor; gait normal |
| Psychiatric | Calm and engaged; no thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). Dr. Mbatha-Rasmussen confirms chronic kidney disease: a creatinine of 1.7 mg/dL fourteen months ago and 1.98 now, eGFR 42 to 43 and urine albumin 240 mg/g. Normal-sized echogenic kidneys without stones or obstruction and a bland urine sediment point to hypertensive kidney disease with a contribution from two years of daily naproxen; a biopsy is not needed now. Five-year kidney failure risk about 5 percent. Hepatitis B, hepatitis C and HIV serology drawn today. **S**
   - Continue losartan; raise to 100 mg at six weeks if potassium allows.
   - Dapagliflozin once he has been abstinent for some weeks and is eating regularly.
   - 25-hydroxyvitamin D, missed at intake, with the next blood test.
   - Nephrology review in three months.
2. **Hypertensive chronic kidney disease** (I12.9). 146/92, from 158/98. Target below 120 systolic by standardized measurement if tolerated. **S**
   - Less salt; home readings.
3. **Alcohol use disorder, severe** (F10.20). Withdrawal completed safely; twelve days without alcohol. With Dr. Mbatha-Rasmussen he chose naltrexone, which needs no dose change at his kidney function, over acamprosate, which would need a lower dose at his creatinine clearance of about 58 mL/min and three doses a day. Liver tests are falling and well under three times normal; no opioid use. Safety reviewed: no thoughts of suicide or self-harm; firearms locked; 988 card carried. **S**
   - Naltrexone 50 mg every morning from today, with a wallet card.
   - Counseling weekly; continue thiamine.
4. **Alcohol-associated fatty liver** (K70.0). FIB-4 2.28 was indeterminate; liver stiffness 7.2 kPa makes advanced fibrosis unlikely, though stiffness can read high soon after heavy drinking. Abstinence is the treatment. **S**
   - Liver tests at six weeks.
5. **Naproxen use** (Z79.1). Stopped; acetaminophen is controlling the knee pain. **S**
   - No oral anti-inflammatory medicines.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 146/92 mmHg |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Two weeks after losartan 50 mg: potassium 4.9 mmol/L; creatinine 2.04 mg/dL, up 3 percent; eGFR 42 |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Up to date | eGFR 43 and urine albumin 240 mg/g at intake; with a creatinine of 1.7 mg/dL fourteen months ago, chronic for more than three months |
| Laboratory | Urinalysis with microscopy | At diagnosis | Up to date | Bland at intake: 2+ protein, no blood, casts or crystals |
| Imaging | Kidney ultrasound | At diagnosis of chronic kidney disease of unclear cause | Completed today | Kidneys 10.8 and 11.0 cm, echogenic, no stones or obstruction |
| Laboratory | Calcium, phosphate and PTH | G3a to G3b: every six to twelve months | Up to date | Calcium 9.2 and phosphate 3.8 mg/dL; PTH 74 pg/mL, mildly high, at intake |
| Laboratory | 25-hydroxyvitamin D | At baseline | Deferred | The baseline 25-hydroxyvitamin D was left off the intake order and was not drawn. PTH is only mildly high and calcium and phosphate are normal, so no harm is likely from a delay of a few weeks. Corrective action: added to the next blood draw, and the clinic's new-CKD order set checked |
| Laboratory | Hemoglobin | G3: at least yearly | Up to date | 13.6 g/dL at intake |
| Laboratory | Lipid panel | Once at diagnosis | Up to date | LDL 128 mg/dL at intake; statin not indicated at 39 |
| Survey | Kidney failure risk equation (2- and 5-year) | Yearly in G3 to G5, and before referral decisions | Completed today | Five-year risk about 5 percent; two-year about 1.5 percent |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | Naproxen stopped; acetaminophen within 2,000 mg a day |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Sodium below 2 g a day explained; protein about 0.8 g/kg |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | None for twelve days |
| Medication safety | Withdrawal monitoring (CIWA-Ar) and thiamine | During withdrawal; thiamine throughout early recovery | Completed today | Withdrawal completed with a peak CIWA-Ar of 11 on day 2; no seizures or hallucinations; thiamine continued |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Completed today | Before naltrexone: AST 49, ALT 36, GGT 141 U/L, falling |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | At the start and every visit | Completed today | No opioid use; wallet card given; started today |
| Imaging | Liver fibrosis: FIB-4, then elastography if indeterminate | At diagnosis of alcohol-associated liver disease | Completed today | FIB-4 2.28 at intake; liver stiffness 7.2 kPa today |
| Referral | Nephrology consultation | At diagnosis, with a five-year kidney failure risk of 3 to 5 percent or more | Completed today | Seen by Dr. Mbatha-Rasmussen today |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery | Completed today | First session done; weekly from now |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked with the ammunition apart; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | About ten a day; not ready to stop |

## Goal progress

- Find out how much kidney function is lost, how long it has been so, and why. Outcome by 1915-08-18: Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected. **S**
- Stop drinking safely, and stay stopped. In progress; target 1916-02-02. **S**
- Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80. In progress; target 1916-02-02. **S**
- Urine albumin down by at least 30 percent. In progress; target 1915-10-27. **S**
- No anti-inflammatory pain medicines, and pain controlled. In progress; target 1915-10-27. **S**
- Keep the morning writing hours. In progress; target 1915-10-27. **S**

## Medication changes

- Started: Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Six-week review with potassium, creatinine, urine albumin, liver tests, PEth and vitamin D. Counseling weekly. The clinic or 988 at any hour. **S**
- Next scheduled visit 1915-09-15: six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safety. **S**
